Part 5/13:
The development of a COVID-19 vaccine is complex and collaborative. In Singapore, partnerships with biotech companies like Acturus Therapeutics exemplify this teamwork. Acturus's innovative messenger RNA (mRNA) vaccines, such as the Lunar Cove 19 candidate, utilize genetic material that instructs cells to produce only the virus's spike protein, training the immune system without exposing individuals to the actual virus.
This partnership was facilitated by economic development agencies, emphasizing cross-border cooperation. The mRNA approach offers advantages like lower doses due to self-replicating RNA, making large-scale vaccination more feasible.